Revenue
2019
2020
2021
2022
2023
2024
2025
Bioventus Inc. (BVS)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M | $321.2M | $340.1M |
| Gross profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M | $233.5M | $249.2M |
| Research & development | $12.1M | $14.0M | $13.4M | $23.9M | $19.0M | $11.2M | $11.1M |
| Operating income | $54.0M | −$15.2M | −$81.7M | −$167.2M | $12.1M | $21.2M | $31.2M |
| EBITDAderived | $101.0M | $34.4M | −$24.4M | −$111.8M | $46.9M | $49.9M | $61.5M |
| Net income | $22.7M | −$36.1M | −$156.2M | −$158.7M | $19.4M | $16.4M | $6.9M |
| Basic EPSper diluted share | $0.34 | -$0.56 | -$2.49 | -$2.59 | -$0.15 | — | — |
| Diluted EPSper diluted share | $0.33 | -$0.56 | -$2.49 | -$2.59 | -$0.15 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 11, 2026Form 4 | McMurry-Heath MichelleDirector | SellClass A Common Stock | 12.0K | $8.79 | $105.5K | 45.0K |
| Dec 4, 2025Form 4 | NOHRA GUY PDirector | SellClass A Common Stock | 10.0K | $7.57 | $75.7K | 116.6K |
| Nov 7, 2025Form 4 | McMurry-Heath MichelleDirector | SellClass A Common Stock | 17.7K | $7.42 | $131.3K | 57.0K |
| Apr 11, 2025Form 4 · 10b5-1 | Singleton Mark LeonardSVP & CFO | SellClass A Common Stock | 3.9K | $7.57 | $29.3K | 141.1K |
| Apr 11, 2025Form 4 · 10b5-1 | D'Adamio AnthonySVP & General Counsel | SellClass A Common Stock | 3.0K | $7.57 | $22.4K | 131.4K |